The Sarcomeric Human Cardiomyopathy Registry (ShaRe) has been set up to advance our understanding of Hypertrophic Cardiomyopathy (HCM) and Dilated Cardiomyopathy (DCM). These heritable heart diseases are caused by mutations in the protein genes of the sarcomere, the fundamental contractile unit of heart muscle. They are genetically passed on in families in an autosomal dominant pattern of inheritance. The prevalence of these diseases, taken together, is usually estimated at 1 in 500 individuals in the general population.
A Cardiomyopathy Registry
By contributing de-identified clinical and laboratory data from the patients and families under their care, these investigators are making this registry one of the largest and most detailed data sets of its kind in this disease area.
Funded by research grants from MyoKardia, Inc., SHaRe brings together a group of experienced, knowledgeable cardiologists and geneticists from the United States and Europe with a passion for helping people with genetic heart disease.
MyoKardia’s mission is to revolutionize the treatment of genetic cardiomyopathies and related heart diseases through advances in sarcomere-related biochemistry and molecular biology.
To download our brochure, click here.
Stay Connected: Join our mailing list for updates on research, treatments, clinical trials and events.
International SHaRe Locations Around the World
Hover over and/or click a site for more information.
- Dr. Carolyn Ho - Brigham & Women's Hospital, U.S.
- Dr. Euan Ashley - Stanford University, U.S.
- Dr. Charlene Day - University of Michigan, U.S.
- Dr. Iacapo Olivotto - Careggi University Hospital, Italy
- Dr. William McKenna - University College London, U.K.
- Dr. Michelle Michels - Erasmus University Hospital, Netherlands
- Dr. Steven Colan - Boston Children's Hospital, U.S.